Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

OBJECTIVE: This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. BACKGROUND: Pemigatinib provided clinical benefits for previously treate...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Guo‐Ming, Huang, Xiao‐Yong, Wen, Tian‐Fu, Song, Tian‐Qiang, Kuang, Ming, Mou, Hai‐Bo, Bao, Le‐Qun, Zhao, Hai‐Tao, Zhao, Hong, Feng, Xie‐Lin, Zhang, Bi‐Xiang, Peng, Tao, Zhang, Yu‐Bao, Li, Xiang‐Cheng, Yu, Hong‐Sheng, Cao, Yu, Liu, Lian‐Xin, Zhang, Ti, Wang, Wei‐Lin, Ran, Jiang‐Hua, Liu, Ying‐Bin, Gong, Wei, Chen, Ming‐Xia, Cao, Lian, Luo, Yang, Wang, Yan, Zhou, Hui, Yang, Guo‐Huan, Fan, Jia, Zhou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972033/
https://www.ncbi.nlm.nih.gov/pubmed/36127767
http://dx.doi.org/10.1002/cam4.5273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972033/
https://www.ncbi.nlm.nih.gov/pubmed/36127767
http://dx.doi.org/10.1002/cam4.5273

Ejemplares similares